Physician profile
Frederick B Durer
NPI 1982601027
$3,181.49
in general payments reported to CMS, 2019-2025
32 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $391 · 2021: $279 · 2022: $497 · 2023: $513 · 2024: $723 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.56 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $820.94 | 2019-2025 | Liletta, Ubrelvy |
| Astellas Pharma US INC | $369.42 | 2019-2025 | Veozah |
| Exeltis, USA INC. | $287.93 | 2020-2024 | Slynd |
| Hologic Sales and Service, LLC | $178.86 | 2019-2021 | |
| Pfizer INC. | $164.38 | 2019-2024 | |
| Agile Therapeutics, INC. | $137.50 | 2022-2024 | Twirla |
| Exact Sciences Corporation | $126.36 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $111.63 | 2022-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $105.17 | 2023-2024 | Myfembree |
| Sage Therapeutics, LLC | $96.93 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $86.33 | 2020-2022 | |
| Daiichi Sankyo INC. | $77.97 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.08 | 2019-2025 | |
| Amgen INC. | $69.58 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $45.96 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $41.25 | 2020 | |
| Amag Pharmaceuticals, INC. | $40.79 | 2019-2020 | |
| Therapeuticsmd, INC. | $40.23 | 2019-2021 | |
| Lilly USA, LLC | $39.93 | 2024 | Zepbound |
| Merck Sharp & Dohme LLC | $38.54 | 2019-2020 | |
| Ethicon US, LLC | $36.36 | 2019-2024 | Stratafix |
| Minerva Surgical, INC | $26.94 | 2019-2023 | |
| Pharmacosmos Therapeutics INC. | $22.01 | 2022 | |
| Novo Nordisk INC | $21.90 | 2024 | Wegovy |
| Mylan Pharmaceuticals INC. | $20.49 | 2022 | |
| Evofem Biosciences, INC. | $15.89 | 2021 | |
| Allergan, INC. | $14.81 | 2019 | |
| Duchesnay USA Incorporated | $14.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.17 | 2024 | Xifaxan |
| Vertical Pharmaceuticals, LLC | $14.06 | 2019 | |
| Myovant Sciences INC. | $12.44 | 2021 | |
| Meditrina | $12.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Durer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.